Brain Changes During Social Reward Psychotherapy for Mid- and Late-Life Suicidality

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

128 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-09-18

Study Completion Date

2028-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators hypothesized that during the 9-week course of Engage \& Connect treatment there will be an increase in brain functions of the Positive Valence System which in turn will lead to reduction in suicidality.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Social Reward and Its Effect on Brain Functions in Psychotherapies for Mid- and Late-Life Depression

NCT04487730

Major Depressive Disorder

COMPLETED NA

Reward Function and Therapy for Late-Life Depression

NCT03688139

Major Depressive Disorder

COMPLETED NA

Reaching and Engaging Depressed Senior Center Clients (REDS)

NCT03246789

Depression, Unipolar Mental Health Disorder

COMPLETED NA

Reaching and Engaging Depressed Senior Center Clients

NCT04289298

Depression in Old Age

COMPLETED NA

Effect of Suicidality on Social Cognition

NCT06163612

Suicide Major Depressive Disorder

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Social disconnection peaks in middle and late life and leads to an increased risk of suicide, persistent depression, and poor response to psychosocial interventions. There is a critical need to develop a mechanistic understanding of the link between social disconnection and suicidality, identify biological targets, and address targets with scalable interventions. The investigators developed a novel psychotherapy, Engage \& Connect, aimed to improve functions of the Positive Valence System (PVS) that are impaired in suicidality through increased engagement in rewarding social activities. This study will use state-of-the-art precision imaging methods and clinical measures to evaluate brain- and behavioral changes in the PVS during psychotherapy.

Participants will:

* Be randomly assigned to 9-weekly sessions of either Engage \& Connect therapy or Symptom Review and Psychoeducation
* Complete 4 research assessments
* Complete 3 MRI scans

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression Suicidal Ideation Major Depressive Disorder Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

"Engage & Connect" Psychotherapy

Engage \& Connect is a remotely-delivered psychotherapy, aimed to increase engagement in rewarding social activities and in turn, reduce suicidality. In Engage \& Connect, depressed middle-aged and older adults with suicidal ideation work with a therapist to develop "action plans" to pursue rewarding social activities of their choice.

Group Type EXPERIMENTAL

"Engage & Connect" Psychotherapy

Intervention Type BEHAVIORAL

9-weeks of weekly psychotherapy sessions focused on social reward exposure

Symptom Review and Psychoeducation (SRP)

In this intervention, the therapist will review the participant's symptoms and provide literature-based clinical explanations and clarifications about the symptoms, the course, and the causes of depression and aging processes. In SRP, the therapist reviews the depressed individual's symptoms, and level of information on depression, identifies misconceptions, and guides selection of educational material which could benefit the patient.

Group Type ACTIVE_COMPARATOR

Symptom Review and Psychoeducation (SRP)

Intervention Type BEHAVIORAL

9-weeks of weekly psychotherapy sessions focused on symptom review and psychoeducation about depression and aging

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

"Engage & Connect" Psychotherapy

9-weeks of weekly psychotherapy sessions focused on social reward exposure

Intervention Type BEHAVIORAL

Symptom Review and Psychoeducation (SRP)

9-weeks of weekly psychotherapy sessions focused on symptom review and psychoeducation about depression and aging

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ages aged 50-80 \[stratified so that 50% are older than 65\]
* Endorsement of Suicidal Ideation \[Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders-5 (SCID-5) Suicide Item (Item 9) with a score of 2
* Major Depressive Disorder as determined by the SCID-5
* Depression Rating Scale \[Montgomery-Åsberg Depression Rating Scale (MADRS)\] score of 16 or greater.
* Mini Mental Status Exam (MMSE) equal or greater than a score of 23
* Off antidepressants or on a stable dose of an antidepressant for 8 weeks and do not intend to change the dose in the next 10 weeks, without individual psychotherapy services during the study period.
* Capacity to provide consent for research assessment and treatment.

Exclusion Criteria

* Intent or plan to attempt suicide in the near future.
* History or presence of psychiatric diagnoses other than major depressive disorder without psychotic features, generalized anxiety disorder, or specific phobia.
* Use of psychotropic drugs or cholinesterase inhibitors other than use of 0.5 mg or less of lorazepam daily up to seven times per week.
* Neurological disorders (dementias, amnestic and multidomain Mild Cognitive Impairment, Parkinson's disease, epilepsy, etc.).
* Acute or severe medical illness in the past 3 months (metastatic cancer, multiple sclerosis, decompensated cardiac, liver or kidney failure, major surgery, stroke or myocardial infarction, cardiac, renal, or respiratory failure; severe chronic obstructive pulmonary disease, etc.) that may be the primary cause depressive symptoms, influence brain systems of interest, or impact ability to participate in the study.
* Contraindications to MRI scanning including cardiac pacemaker, heart valve replacement, vascular stent, insulin pump, cochlear implant, any other metallic biomedical implant contraindicating to MRI, and claustrophobia.

Minimum Eligible Age

50 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No